clinical trial · NCT06719141
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
Developmental and Epileptic EncephalopathyLP352Placebo
brief summary
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
started
Nov 11, 2024
primary completion
Oct 31, 2026
completion
Nov 30, 2026
last updated
Apr 15, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol